Assertio Historical Income Statement

ASRT Stock

USD 1.01 0.07 7.45%

Historical analysis of Assertio Therapeutics income statement accounts such as Total Revenue of 128 M, Gross Profit of 112.5 M or Other Operating Expenses of 415.4 M can show how well Assertio Therapeutics performed in making a profits. Evaluating Assertio Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Assertio Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Assertio Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Assertio Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assertio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.

About Assertio Income Statement Analysis

Assertio Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Assertio Therapeutics shareholders. The income statement also shows Assertio investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Assertio Therapeutics Income Statement Chart

At this time, Assertio Therapeutics' Non Recurring is comparatively stable compared to the past year. Reconciled Depreciation is likely to gain to about 49.4 M in 2024, whereas Gross Profit is likely to drop slightly above 112.5 M in 2024.

Gross Profit Other Operating Expenses Total Operating Expenses Net Interest Income

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Assertio Therapeutics minus its cost of goods sold. It is profit before Assertio Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Assertio Therapeutics. It is also known as Assertio Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Net Interest Income

The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.

Most accounts from Assertio Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Assertio Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assertio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.At this time, Assertio Therapeutics' Non Recurring is comparatively stable compared to the past year. Reconciled Depreciation is likely to gain to about 49.4 M in 2024, whereas Gross Profit is likely to drop slightly above 112.5 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	95.2M	137.5M	125.0M	112.5M
Total Revenue	111.0M	156.2M	152.1M	128.0M

Gross Profit Total Revenue

Assertio Therapeutics income statement Correlations

	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Depreciation And Amortization	Cost Of Revenue	Income Before Tax	Total Other Income Expense Net	Selling General Administrative	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Operating Income Net Other	Tax Provision	Interest Income	Non Recurring	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Interest Expense		0.85	0.81	0.62	0.15	0.21	0.68	0.51	0.56	-0.1	-0.13	0.95	0.77	-0.15	-0.15	0.85	-0.42	-0.13	-0.25	-0.5	-0.69	-0.35	-0.36	0.44	-0.3
Total Revenue	0.85		0.99	0.63	0.33	0.36	0.6	0.58	0.57	0.04	0.14	0.73	0.76	0.1	-0.05	0.83	-0.46	-0.02	-0.41	-0.29	-0.59	-0.38	-0.38	0.42	-0.19
Gross Profit	0.81	0.99		0.55	0.41	0.44	0.52	0.64	0.51	0.09	0.17	0.69	0.66	0.17	-0.09	0.78	-0.45	0.03	-0.44	-0.24	-0.55	-0.4	-0.4	0.45	-0.21
Other Operating Expenses	0.62	0.63	0.55		-0.52	-0.5	0.58	-0.24	0.99	-0.68	0.34	0.65	0.78	-0.63	0.0	0.72	-0.43	-0.72	0.14	-0.14	-0.55	0.11	0.05	0.02	0.46
Operating Income	0.15	0.33	0.41	-0.52		0.98	-0.02	0.9	-0.57	0.86	-0.25	-0.03	-0.13	0.88	-0.04	0.04	0.08	0.85	-0.63	-0.11	0.1	-0.53	-0.48	0.46	-0.76
Ebit	0.21	0.36	0.44	-0.5	0.98		-0.06	0.94	-0.55	0.83	-0.22	0.03	-0.11	0.85	-0.07	0.09	-0.05	0.82	-0.61	-0.14	0.0	-0.52	-0.45	0.43	-0.77
Research Development	0.68	0.6	0.52	0.58	-0.02	-0.06		0.13	0.52	-0.07	-0.26	0.53	0.76	-0.17	0.17	0.81	-0.18	-0.09	-0.38	-0.33	-0.17	-0.42	-0.49	0.46	-0.23
Ebitda	0.51	0.58	0.64	-0.24	0.9	0.94	0.13		-0.3	0.68	-0.25	0.37	0.14	0.67	-0.16	0.33	-0.21	0.66	-0.55	-0.32	-0.26	-0.52	-0.46	0.49	-0.76
Total Operating Expenses	0.56	0.57	0.51	0.99	-0.57	-0.55	0.52	-0.3		-0.73	0.4	0.61	0.7	-0.67	-0.04	0.65	-0.42	-0.77	0.19	-0.09	-0.51	0.15	0.08	-0.01	0.53
Net Income	-0.1	0.04	0.09	-0.68	0.86	0.83	-0.07	0.68	-0.73		-0.48	-0.27	-0.23	0.95	0.34	-0.15	0.18	0.99	-0.58	-0.15	0.19	-0.55	-0.36	0.27	-0.75
Income Tax Expense	-0.13	0.14	0.17	0.34	-0.25	-0.22	-0.26	-0.25	0.4	-0.48		-0.13	-0.02	-0.18	-0.04	0.02	0.01	-0.47	0.04	0.66	-0.1	0.17	0.09	-0.07	0.62
Depreciation And Amortization	0.95	0.73	0.69	0.65	-0.03	0.03	0.53	0.37	0.61	-0.27	-0.13		0.7	-0.35	-0.29	0.7	-0.45	-0.3	0.03	-0.57	-0.77	-0.11	-0.12	0.25	-0.15
Cost Of Revenue	0.77	0.76	0.66	0.78	-0.13	-0.11	0.76	0.14	0.7	-0.23	-0.02	0.7		-0.26	0.16	0.85	-0.37	-0.26	-0.15	-0.39	-0.62	-0.16	-0.17	0.16	-0.02
Income Before Tax	-0.15	0.1	0.17	-0.63	0.88	0.85	-0.17	0.67	-0.67	0.95	-0.18	-0.35	-0.26		0.37	-0.15	0.2	0.94	-0.64	0.07	0.18	-0.56	-0.37	0.28	-0.62
Total Other Income Expense Net	-0.15	-0.05	-0.09	0.0	-0.04	-0.07	0.17	-0.16	-0.04	0.34	-0.04	-0.29	0.16	0.37		0.05	0.21	0.34	-0.33	0.12	-0.06	-0.39	-0.08	-0.07	0.0
Selling General Administrative	0.85	0.83	0.78	0.72	0.04	0.09	0.81	0.33	0.65	-0.15	0.02	0.7	0.85	-0.15	0.05		-0.49	-0.18	-0.39	-0.24	-0.51	-0.4	-0.46	0.48	-0.22
Selling And Marketing Expenses	-0.42	-0.46	-0.45	-0.43	0.08	-0.05	-0.18	-0.21	-0.42	0.18	0.01	-0.45	-0.37	0.2	0.21	-0.49		0.26	-0.17	0.4	0.34	-0.19	-0.22	0.17	-0.02
Net Income From Continuing Ops	-0.13	-0.02	0.03	-0.72	0.85	0.82	-0.09	0.66	-0.77	0.99	-0.47	-0.3	-0.26	0.94	0.34	-0.18	0.26		-0.59	-0.11	0.22	-0.56	-0.38	0.29	-0.75
Non Operating Income Net Other	-0.25	-0.41	-0.44	0.14	-0.63	-0.61	-0.38	-0.55	0.19	-0.58	0.04	0.03	-0.15	-0.64	-0.33	-0.39	-0.17	-0.59		-0.32	-0.04	0.94	0.91	-0.83	0.51
Tax Provision	-0.5	-0.29	-0.24	-0.14	-0.11	-0.14	-0.33	-0.32	-0.09	-0.15	0.66	-0.57	-0.39	0.07	0.12	-0.24	0.4	-0.11	-0.32		0.3	-0.2	-0.32	0.26	0.35
Interest Income	-0.69	-0.59	-0.55	-0.55	0.1	0.0	-0.17	-0.26	-0.51	0.19	-0.1	-0.77	-0.62	0.18	-0.06	-0.51	0.34	0.22	-0.04	0.3		0.12	-0.03	-0.07	-0.01
Non Recurring	-0.35	-0.38	-0.4	0.11	-0.53	-0.52	-0.42	-0.52	0.15	-0.55	0.17	-0.11	-0.16	-0.56	-0.39	-0.4	-0.19	-0.56	0.94	-0.2	0.12		0.9	-0.85	0.53
Net Interest Income	-0.36	-0.38	-0.4	0.05	-0.48	-0.45	-0.49	-0.46	0.08	-0.36	0.09	-0.12	-0.17	-0.37	-0.08	-0.46	-0.22	-0.38	0.91	-0.32	-0.03	0.9		-0.97	0.5
Reconciled Depreciation	0.44	0.42	0.45	0.02	0.46	0.43	0.46	0.49	-0.01	0.27	-0.07	0.25	0.16	0.28	-0.07	0.48	0.17	0.29	-0.83	0.26	-0.07	-0.85	-0.97		-0.5
Extraordinary Items	-0.3	-0.19	-0.21	0.46	-0.76	-0.77	-0.23	-0.76	0.53	-0.75	0.62	-0.15	-0.02	-0.62	0.0	-0.22	-0.02	-0.75	0.51	0.35	-0.01	0.53	0.5	-0.5

Click cells to compare fundamentals

Assertio Therapeutics Account Relationship Matchups

Assertio Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	58.4M	15.9M	10.2M	8.0M	3.4M	3.2M
Total Revenue	229.5M	106.3M	111.0M	156.2M	152.1M	128.0M
Gross Profit	220.0M	86.4M	95.2M	137.5M	125.0M	112.5M
Other Operating Expenses	230.3M	153.2M	100.5M	98.1M	395.6M	415.4M
Operating Income	3.2M	(46.9M)	9.4M	57.8M	(243.5M)	(231.4M)
Ebit	3.2M	(29.6M)	9.7M	39.1M	(250.7M)	(238.1M)
Research Development	8.0M	10.1M	4.2M	0.0	2.8M	2.7M
Ebitda	105.0M	(3.2M)	38.8M	72.5M	(222.4M)	(211.3M)
Total Operating Expenses	220.7M	133.3M	84.7M	79.4M	368.6M	387.0M
Net Income	(217.2M)	(28.1M)	(1.3M)	109.6M	(331.9M)	(315.3M)
Income Tax Expense	(5.3M)	(17.4M)	728K	(78.5M)	77.9M	81.8M
Cost Of Revenue	9.5M	19.9M	15.8M	18.7M	27.0M	20.2M
Income Before Tax	(222.5M)	(45.5M)	(553K)	31.2M	(254.1M)	(241.4M)
Total Other Income Expense Net	(225.7M)	36.6M	(10.0M)	(26.6M)	(10.5M)	(10.0M)
Selling General Administrative	108.1M	103.9M	54.8M	43.4M	65.3M	101.7M
Net Income Applicable To Common Shares	(217.2M)	(28.1M)	(1.3M)	109.6M	98.7M	103.6M
Net Income From Continuing Ops	(217.2M)	(28.1M)	(1.3M)	109.6M	(331.9M)	(315.3M)
Tax Provision	(5.3M)	(17.4M)	728K	(78.5M)	77.9M	81.8M
Net Interest Income	(58.4M)	(15.9M)	(10.2M)	(8.0M)	(13.3M)	(14.0M)
Reconciled Depreciation	102.9M	26.4M	29.1M	33.4M	28.2M	49.4M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Assertio Stock Analysis

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Assertio Historical Income Statement

About Assertio Income Statement Analysis

Assertio Therapeutics Income Statement Chart

Gross Profit

Other Operating Expenses

Total Operating Expenses

Net Interest Income

Assertio Therapeutics income statement Correlations

Assertio Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Assertio Therapeutics income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Assertio Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 0.99	Total Revenue
Total Operating Expenses	+ 0.99	Other Operating Expenses
Net Income From Continuing Ops	+ 0.99	Net Income
Ebit	+ 0.98	Operating Income
Depreciation And Amortization	+ 0.95	Interest Expense
Income Before Tax	+ 0.95	Net Income

Reconciled Depreciation	- 0.97	Net Interest Income
Reconciled Depreciation	- 0.85	Non Recurring
Reconciled Depreciation	- 0.83	Non Operating Income Net Other
Interest Income	- 0.77	Depreciation And Amortization
Net Income From Continuing Ops	- 0.77	Total Operating Expenses
Extraordinary Items	- 0.77	Ebit